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Context: Hypoglycemia is emerging as a risk for cardiovascular events in diabetes. We hypothesized
that hypoglycemia activates the innate immune system, which is known to increase cardiovascular risk.
Objective: To determine whether hypoglycemia modifies subsequent innate immune system responses.
Design and Setting: Single-blinded, prospective study of three independent parallel groups.
Participants and Interventions: Twenty-four healthy participants underwent either a hyperinsulinemic-
hypoglycemic (2.5mmol/L), euglycemic (6.0mmol/L), or sham-saline clamp (n = 8 for each group). After
48 hours, all participants received low-dose (0.3 ng/kg) intravenous endotoxin.
Main Outcome Measures: We studied in-vivo monocyte mobilization and monocyte-platelet
interactions.
Results: Hypoglycemia increased total leukocytes (9.98 6 1.14 3 109/L vs euglycemia 4.38 6 0.53 3
109/L,P,0.001; vs sham-saline 4.766 0.363 109/L,P,0.001) (mean6 SEM),mobilizedproinflammatory
intermediatemonocytes (42.206 7.52/mL vs euglycemia 20.666 3.43/mL, P, 0.01; vs sham-saline 26.206
3.86/mL, P, 0.05), andnonclassicmonocytes (36.166 4.66/mL vs euglycemia 12.726 2.42/mL, P, 0.001; vs
sham-saline 19.056 3.81/mL, P, 0.001). Following hypoglycemia vs euglycemia, platelet aggregation to
agonist (area under the curve) increased (73.87 6 7.30 vs 52.50 6 4.04, P , 0.05) and formation of
monocyte-platelet aggregates increased (96.056 14.51/mL vs 49.326 6.41/mL,P,0.05).Withinmonocyte
subsets, hypoglycemia increased aggregation of intermediatemonocytes (10.516 1.42/mL vs euglycemia
4.196 1.08/mL,P,0.05; vs sham-saline 3.816 1.42/mL,P,0.05) andnonclassicmonocytes (9.536 1.08/mL
vs euglycemia 2.866 0.72/mL, P, 0.01; vs sham-saline 3.086 1.01/mL, P, 0.05), with platelets compared
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with controls. Hypoglycemia led to greater leukocyte mobilization in response to subsequent low-dose
endotoxin challenge (10.96 6 0.97 vs euglycemia 8.21 6 0.85 3 109/L, P , 0.05).
Conclusions:Hypoglycemiamobilizes monocytes, increases platelet reactivity, promotes interaction
between platelets and proinflammatory monocytes, and potentiates the subsequent immune
response to endotoxin. These changes may contribute to increased cardiovascular risk observed in
people with diabetes. (J Clin Endocrinol Metab 104: 1187–1199, 2019)
Hypoglycemia is associated with a greater propensityto adverse cardiovascular (CV) outcomes in diabetes
(1–3). To determine whether such outcomes were de-
pendent on changes in innate immune responses, we
devised a model whereby subjects were challenged with a
hypoglycemic clamp, and then the durable effects on the
innate immune system were probed by an in vivo en-
dotoxin challenge 48 hours later.
Iatrogenic hypoglycemia remains a major barrier to
effective treatment of insulin-treated diabetes (4). The
Action to Control Cardiovascular Risk in Diabetes trial
showed that intensive glucose control, during which
patients were exposed to significantly more hypoglyce-
mia (5), was associated with excess CVmortality. Despite
the evidence confirming an association between hypo-
glycemia and mortality, cause and effect has not been
established. Trial evidence suggests that the relationship
is, at least in part, explained by confounding, that is, that
hypoglycemia identifies patients with comorbidities who
are both vulnerable to hypoglycemia and more likely to
die for other reasons (6). Nevertheless, a recent large
meta-analysis (7) suggested that comorbidities alone are
unlikely to explain this relationship. Furthermore, there
is a growing body of evidence highlighting a number of
mechanisms whereby hypoglycemia may lead to CV
events (8, 9).
Hypoglycemia has proinflammatory consequences,
including increases in levels of factor VIII and von
Willebrand factor and impaired fibrinolysis (10–12). In
addition, hypoglycemia has been shown to increase
proinflammatory cytokines (12–14) and promote rises in
the levels of proatherogenic cell adhesion molecules (12).
Repeated episodes of hypoglycemia have also been re-
ported to impair nitric oxide–mediated vasodilation (15).
Monocytes are phagocytes that are central to the
etiology of atherosclerosis (16) and play a role in pre-
cipitating acute CV events by promoting plaque de-
stabilization and rupture (17). The extent to which
monocytosis and monocyte activation are modified by
hypoglycemia remains uncertain. Recent studies
have also determined that monocytes can be classi-
fied into three distinct subsets, called classic mono-
cytes (CMs: CD14++ CD162, and Mon1), intermediate
monocytes (IMs: CD14++CD16+, Mon2), and nonclassic
monocytes (NCMs: CD14+ CD16++, Mon3) (18, 19). A
number of observational studies indicate that IMsmay be
particularly proatherogenic. Elevated levels of IMs are
associatedwith adverseCVoutcomes (20–23), independently
predict future CV events (22), and have been associated with
coronary plaque vulnerability in patients with angina (24).
Elevated levels of CMs may also independently predict CV
events (25).
Acute myocardial infarction results in monocytosis,
mediated by sympathetic nervous system activation (26).
In humans, CD16+ monocytes selectively mobilize, in a
catecholamine-dependent fashion, after exercise (27).
Because epinephrine is the key counterregulatory hormone
produced in response to hypoglycemia, we hypothesized
that hypoglycemia would also exert significant effects on
monocytes. We further hypothesized that we would see
additional synergistic changes in monocyte and platelet
activation, as revealed by formation of monocyte-
platelet aggregates (MPAs), which are increased after
acute myocardial infarction (20, 28). In large pro-
spective studies, CV events did not appear to occur
during the hypoglycemic episode per se, but there was
an increased risk of events in the weeks andmonths after
the episode (29–31). Therefore, we hypothesized that
acute hypoglycemia may prime the innate immune
system, leading to a more pronounced inflammatory
response to a subsequent inflammatory stimulus down-
stream from the initial episode of hypoglycemia. It is also
relevant to note that people with diabetes experience
increased incidences of acute and chronic infections that
will further activate innate immunity. To reveal whether
hypoglycemia modulated monocyte function in the hu-
man in vivo, we chose to combine a classic hypoglycemic
stimulus with a subsequent in vivo systemic stimulus of
the innate immune system. To do so, we combined
hyperinsulinemic-hypoglycemic, euglycemic, and sham-
saline clamps with low-dose intravenous endotoxin
challenge 48 hours later in healthy participants. Endo-
toxin, otherwise known as gram-negative bacterial
lipopolysaccharide, was used because it induces a short-
lived, sterile inflammation that is both safe and repro-
ducible (32).
1188 Iqbal et al Hypoglycemia Modulates Innate Immune Responses J Clin Endocrinol Metab, April 2019, 104(4):1187–1199
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Materials and Methods
Study design and participants
This was a single-blinded, prospective study of three in-
dependent parallel groups (hyperinsulinemic-hypoglycemia,
euglycemia, and sham-saline controls) conducted in a ran-
dom group order at the Clinical Research Facility, Northern
General Hospital, Sheffield, United Kingdom between January
2015 and April 2016. We therefore had three groups that had
euglycemia with insulin, hypoglycemia with insulin, or saline.
Each then received endotoxin. Baseline values at the start
of endotoxin administration were studied in all groups, pro-
viding a set of data obtained before endotoxin. A total of 24
healthy participants without diabetes were recruited from the
University of Sheffield and Sheffield Teaching Hospitals, with
written informed consent in accordance with a protocol ap-
proved by Yorkshire and the Humber-Sheffield Research
Ethics Committee (REC 14/YH/1264). All participants had a
HbA1c ,6.5% (,48 mmol/mol), measured with ion exchange
high-performance liquid chromatography, and none had im-
paired glucose tolerance based on HbA1c as judged by the
American Diabetes Association criteria (33, 34). Participants
were in good health, as determined by amedical history, physical
examination, vital signs, and clinical laboratory test results in-
cluding full blood count and renal and liver function. Those with
an intercurrent illness in the previous 4 weeks were excluded.
Participants taking beta-blockers, QT interval–prolonging agents,
and anticoagulant, antiplatelet, or anti-inflammatory medica-
tions were also excluded. Female participants were on secure
contraception and also had negative urinary pregnancy tests on
the morning of the clamp and endotoxin studies.
Clamp studies
All participants attended at 0800 hours after an overnight
fast and were blinded to their group allocation. Participants
were instructed to avoid caffeine, alcohol, and vigorous exercise
24 hours before the study visit. An intravenous cannula was
inserted into the antecubital fossa of the nondominant arm for
insulin and dextrose infusion. A second intravenous cannula
was inserted into the antecubital fossa of the dominant arm for
all blood measurements except glucose. After application of a
local anesthetic cream (lidocaine/prilocaine; Astra-Zeneca,
Macclesfield, UK) to the dorsal hand or wrist of the non-
dominant arm, a retrograde cannula was inserted and the hand
placed in a warming chamber (The Sheffield Hand Warmer,
Sheffield, UK) at 55°C to allow arterialization of venous blood
for glucose measurement. In the hypoglycemia and euglycemia
study groups, a primed continuous insulin (Human Actrapid;
Novo Nordisk Pharmaceuticals LT, Crawley, UK) infusion was
administered at a rate of 90 mU/m2/min, with total insulin
exposure matched between groups. A 20% dextrose (Baxter
Healthcare Ltd., Thetford, UK) variable-rate infusion was
administered simultaneously and the rate adjusted according to
arterialized whole blood glucose concentrationsmeasured every
5 minutes with a glucose oxidase method (Yellow Springs In-
strument 2300 STAT, Yellow Springs, Ohio). After a brief
(30-minute) euglycemic phase in both groups, blood glucosewas
lowered to 2.5 mmol/L in the hypoglycemia group and main-
tained for 60 minutes at this level. In the euglycemia group,
blood glucose was maintained at 6 mmol/L for 60 minutes.
Participants in the sham-saline group were investigated identi-
cally but did not receive insulin/dextrose infusions and instead
received a slow intravenous infusion of 0.9% NaCl (Baxter,
Baxter Healthcare Ltd.) at a predetermined fixed rate. Thus,
participants in the sham-saline groupwere under normoglycemic
conditions, allowing us to control for the effects of insulin and
dextrose. Blood was sampled at baseline and at 60 minutes.
Members of staff processing assays were blinded to glucose
group allocation.
Endotoxin challenge
Endotoxin challenge is a safe and well-studied model of
innate immune activation in vivo (35). Forty-eight hours after
the clamp, participants reattended at 0800 hours, having fasted
overnight and refrained from caffeine, alcohol, and vigorous
exercise since the clamp visit. An intravenous cannula was
inserted into the antecubital fossa of the nondominant arm for
administration of endotoxin and a second cannula inserted into
the contralateral antecubital fossa for blood sampling. All
participants received 0.3 ng/kg Escherichia coli O:113 lipo-
polysaccharide (Clinical Centre Reference Endotoxin; National
Institutes of Health, Bethesda, MD). Endotoxin powder was
reconstituted in 1 mL sterile 0.9% NaCl to form a solution at
a concentration of 1000 ng/mL, which was vortexed for
60 minutes. The weight-adjusted dosage of endotoxin was
obtained from this solution, added to 5 mL of 0.9% NaCl, and
administered as a slow bolus injection over 1 minute. An in-
travenous infusion of 500mL of 0.9%NaCl (Baxter Healthcare
Ltd.) then continued for 4 hours after endotoxin to avoid
hypotension. Venous blood was sampled at baseline and 2, 4,
and 6 hours after endotoxin. All laboratory measurements were
performed by staff blinded to glucose group allocation.
Biochemical analysis
To measure epinephrine, venous forearm blood was col-
lected into chilled lithium heparin tubes and centrifuged at 4°C,
1000g for 10 minutes. The resulting supernatant was stored
at 280°C until assayed by high-performance liquid chroma-
tography. To determine insulin levels, EDTA-anticoagulated
blood was centrifuged at 3000g for 10 minutes, and free insulin
levels were measured in the resulting plasma with an immu-
noassay (Roche Cobas; Roche Diagnostics, Burgess Hill, West
Sussex, UK). Venous blood was centrifuged at 3000g for
10 minutes, and the resulting serum was used to measure
cortisol and GH with an immunoradiometric assay (Roche
Cobas). Sample collection for cortisol and GH was controlled
for time of day across the three study groups.
Cell counts and flow cytometry
Total and differential white blood cell (WBC) and platelet
counts in EDTA-anticoagulated blood were determined with an
automated clinical grade Sysmex cell counter (XN-9000; Sys-
mex, Milton Keynes, UK). For the clamp visit, alternative WBC
counting methods were piloted for the first two subjects in each
group, but these were later deemed less accurate than the
Sysmex cell counter. Data shown in Figs. 2, 3, and 4a, 4c, 4d,
4e, and 4f are Sysmex data from n = 6 in each study group. Flow
cytometry was used to determine MPAs: blood was collected
into tubes containing trisodium citrate dihydrate (3.13% w/v)
and incubated in a heat block at 37°C for 10 minutes; eryth-
rocytes were lysed with fluorescence-activated cell sorting
(FACS) lyse solution (BD, Oxford, UK) and stained with
fluorescein isothiocyanate–conjugated CD16 (BioLegend, London,
doi: 10.1210/jc.2018-01168 https://academic.oup.com/jcem 1189
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UK), allophycocyanin-conjugated CD14 (BioLegend), and phyco-
erythrin (PE)-conjugated CD42a (BD) in addition to matched
isotype controls. Cells were fixedwith FACS Fix (BD) and analyzed
with flow cytometry (Accuri C6 multicolor flow cytometer; BD)
within a consistent time frame for all subjects. Monocytes were
gated based on morphology and CD14 expression. Neutrophils
were gated on morphology and through exclusion of monocytes.
Monocyte-platelet aggregation was determined by measuring
monocytemean fluorescence of the platelet-specific marker CD42a.
To phenotype and enumerate monocyte subsets, anticoagulated
blood was stained with fluorescein isothiocyanate–conjugated
CD16 (BioLegend), allophycocyanin-conjugated CD14 (BioL-
egend), PE-conjugated CD66c (BD), PE-Cy7-conjugated CD11b
(BioLegend), and (PerCP)-eFluor® 710-conjugated CX3C
chemokine receptor 1 (CX3CR1; eBioscience, Altrincham,
UK). Matched isotype controls and a “fluorescence minus
one” strategy optimized compensation. Stained whole blood
was lysed with FACS lyse as above and the pellet resuspended
in PBS before fixation with 1% w/v formaldehyde. Samples
were immediately processed for analysis with flow cytometry
(LSRII; BD). Monocytes were gated based on morphologi-
cal characteristics and through the exclusion of neutrophils
with CD66c. Monocyte subsets were identified based on
relative expression of CD14 and CD16. Flow cytometry data
were analyzed with FlowJo version 10 (FlowJo LLC, Ash-
land, OR).
Platelet aggregation
Platelet aggregation was measured with impedance aggreg-
ometry (Multiplate®; Verum Diagnostica GmBH, Munich,
Germany). Aliquots of 300 mL saline and 300 mL hirudin-
anticoagulated blood were added to the cuvette and incubated
at 37°C for 3 minutes. Then 20 mL ADP (at a final concentration
of 6.45 mM) was added as agonist, and the assay commenced.
The area under the curve was measured, which represents the
level of platelet aggregation.
Statistical analysis
Our pilot data indicated that a sample size of seven par-
ticipants per group would have 90% power to detect a 50%
relative difference in mobilization of monocytes between hy-
poglycemia and controls. Eight subjects were recruited per
group to allow for a 13% dropout rate. Mean baseline mea-
surements of glucose were compared between groups with
ANOVA. Mean measurements of glucose, insulin, and epi-
nephrine at 60 minutes after clamp were compared, adjusting
for clamp baseline measurement, with analysis of covariance. In
the event of unequal variance between groups, a log transform
was applied and the analysis repeated. Longitudinal and between-
group comparisons were made for postendotoxin measure-
ments with mixed effects linear models. For models examining
between-group differences, the baseline endotoxin measure-
ment was included as a covariate. For all mixed-effects linear
models, an autoregressive correlation structure was used to
allow for the correlation between multiple measurements on
the same person. Planned contrasts were made with baseline
and between groups at equivalent time points with Sidak
correction for multiple comparisons. All data are expressed as
mean 6 SEM, unless otherwise specified, and a P , 0.05 was
deemed statistically significant. Analysis was performed in
SPSS version 22.0 (IBM, Chicago, IL).
Results
Participants
Study participants across the three groups were well
matched for age, sex, body mass index, HbA1c, and total
WBC count, with no significant differences at screen-
ing (Table 1). Participant numbers at each stage of study
are illustrated in a flow diagram (Supplemental Flow
Diagram).
Clamp studies
Glucose, insulin, and counterregulatory hormones
Arterialized blood glucose values are shown in Fig. 1a.
The glucose values were 2.516 0.11 mmol/L and 6.046
0.16 mmol/L at the end of the hypoglycemia and
euglycemia clamps, respectively. Glucose values at the
end of the sham-saline clamp were 4.64 6 0.09 mmol/L.
A counterregulatory response to hypoglycemia was ev-
ident, with epinephrine levels during hypoglycemia
(1.87 6 0.25 nmol/L) being significantly higher (P ,
0.001) than those during euglycemia (0.076 0.01 nmol/L)
and sham-saline (0.10 6 0.04 nmol/L) (Fig. 1b). Free in-
sulin levels at the end of clamp were similar between the
hypoglycemia (968.5 6 149.1 pmol/L) and euglycemia
groups (1025.4 6 81.4 pmol/L, P = 0.996) but signif-
icantly higher (P, 0.001) than those in the sham-saline
(31.3 6 6.3 pmol/L) group (Fig. 1c). Serum cortisol and
Table 1. Comparison of Participant Characteristics at Baseline
Parameter Hypoglycemia Euglycemia Sham-Saline P
Total (n = 24) 8 8 8 N/A
Sex, M/F 4/4 4/4 4/4 N/A
Age, y 21 (19–22) 21 (20–23) 21.5 (21–26) 0.299
Body mass index, kg/m2 24 6 2 23 6 2 24 6 4 0.638
HbA1c
% 5.2 6 0.31 5.2 6 0.26 5.1 6 0.14 0.792
mmol/mol 34 6 3.6 33.5 6 2.8 32.6 6 1.4 0.616
Total WBCs, 3109/L 6.26 6 1.42 4.83 6 0.91 4.50 6 1.69 0.102
Data are mean 6 SD or median (interquartile range). P values indicate comparisons between study groups via parametric or nonparametric testing.
1190 Iqbal et al Hypoglycemia Modulates Innate Immune Responses J Clin Endocrinol Metab, April 2019, 104(4):1187–1199
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GHwere significantly higher in the hypoglycemia group
than in the euglycemia and sham-saline groups (Fig. 1d
and 1e).
Total and differential leukocyte count
We determined whether hypoglycemia results in
changes in circulating leukocytes. Hypoglycemia sig-
nificantly increased the total number of WBCs com-
pared with controls (Fig. 2a). There was an increase
across all classes of leukocytes studied, including neutro-
phils (Fig. 2b), lymphocytes (Fig. 2c), and total monocytes
(Fig. 3a).
Monocyte subsets
We sought to determine whether hypoglycemia exerted
specific effects on monocyte subsets associated with car-
diac pathology. Hypoglycemia increased the absolute
number of all three circulating monocyte subsets com-
pared with euglycemia and sham-saline (Fig. 3b–3d). The
number of circulating NCMs after 60 minutes of hypo-
glycemia compared with baseline (17.6 6 2.9 cells/mL)
increased twofold. IM numbers after 60 minutes of hy-
poglycemia compared with baseline (23.2 6 4.5 cells/mL)
increased by a factor of 1.81, and CMs after 60 minutes of
hypoglycemia comparedwithbaseline (442.46 55.3 cells/mL)
increased by a factor of 1.29. There were no significant dif-
ferences in the baseline values of all three monocyte subsets
between the study groups.
Platelet count, aggregation, and MPAs
Activation of platelets and generation of platelet-
leukocyte aggregates contribute to leukocyte mobiliza-
tion and inflammation in the vasculature (36). We
therefore studied platelet number and function and their
Figure 1. Glucose, insulin, and counterregulatory hormones in clamp studies. (a) Arterialized whole blood glucose values during hyperinsulinemic
hypoglycemic, euglycemic, and sham-saline clamps, (b) epinephrine, (c) free insulin, (d) cortisol, and (e) GH values after 60 min of hypoglycemia,
euglycemia, or sham-saline injection. Data are mean (SEM). *P , 0.05; **P , 0.01; ***P , 0.001; ns-nonsignificant; P values are provided for
comparison between study groups. Black circles (and dashed line 1a), hypoglycemia group; open circles, euglycemia group; black triangles (and solid
line 1a), sham-saline group.
doi: 10.1210/jc.2018-01168 https://academic.oup.com/jcem 1191
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interaction with leukocytes. Total platelet count in-
creased in hypoglycemia compared with euglycemia and
sham-saline controls (Fig. 4a). ADP-induced platelet
aggregation increased after 60 minutes of hypoglycemia
vs euglycemia (P = 0.014), and numerically (but not
statistically significantly) higher platelet aggregation was
detected in the hypoglycemia group compared with the
sham-saline group (P = 0.064) (Fig. 4b). The total
number of MPAs increased after 60 minutes of hy-
poglycemia compared with euglycemia (Fig. 4c). Al-
though total MPAs were not significantly higher in the
hypoglycemia group compared with sham-saline
controls at 60 minutes (Fig. 4c), we observed specific
increases in NCM-MPAs and IM-MPAs (Fig. 4d and 4e).
CM-MPAs appeared to increase after 60 minutes of
hypoglycemia vs euglycemia and sham-saline, but this
increase was not statistically significant (P = 0.054)
(Fig. 4f).
Cell surface markers
To further explore the activation state of monocytes
after hypoglycemia, we studied expression levels of
chemokine receptor CX3CR1 and integrin CD11b. Hy-
poglycemia did not alter the expression of CX3CR1 or
CD11b (Supplemental Fig. 1a and 1b).
Endotoxin challenge
To determine whether previous hypoglycemia af-
fected the subsequent response to a classic immune ac-
tivator and thus to reveal whether hypoglycemia had any
longer-lasting effects on the innate immune system, we
performed a low-dose intravenous endotoxin challenge
48 hours after the hypoglycemic challenge in all subjects.
Consistent with the low-dose model used, no fever or
significant change in mean arterial blood pressure was
recorded after endotoxin challenge across the study
groups.
Epinephrine, cortisol, and GH
In contrast to the stress response induced by hypo-
glycemia, epinephrine levels were not significantly dif-
ferent between study groups 6 hours after endotoxin
administration (Fig. 5a). In the hypoglycemia group,
epinephrine levels were 0.15 6 0.04 nmol/L vs 0.06 6
0.01 nmol/L in euglycemia group and 0.096 0.01 nmol/L
in sham-saline group. There were also no differences
detected between groups in serum cortisol and GH levels
after endotoxin administration (Fig. 5b and 5c).However, a
rise compared with baseline in the stress hormone cortisol
was evidentwhereby serum cortisol levels peaked at 4 hours
after endotoxin challenge in all study groups (P = 0.005)
(Fig. 5b).
Total and differential leukocyte count
We observed that antecedent hypoglycemia modu-
lated the subsequent WBC response to endotoxin. Total
Figure 2. Peripheral total WBC, neutrophil, and lymphocyte kinetics
in experimental hypoglycemia and controls. Number of circulating
(a) total WBCs, (b) neutrophils, and (c) lymphocytes after 60 min of
hypoglycemia, euglycemia, or sham-saline injection. Data are mean
(SEM). **P , 0.01; ***P , 0.001; P values are provided for
comparison between study groups. Black circles, hypoglycemia
group; open circles, euglycemia group; black triangles, sham-saline
group.
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9
number of WBCs increased significantly after endotoxin
in all study groups (Fig. 6a). The peak WBC response
occurred at 4 hours after endotoxin, and this level was
significantly higher in the hypoglycemia group at
10.96 6 0.97 3 109/L vs 8.21 6 0.85 3 109/L in the
euglycemia group (P = 0.012) (Fig. 6a). TotalWBC count
4 hours after endotoxin in the sham-saline group was
10.65 6 0.64 3 109/L, and this level was significantly
higher than in the euglycemia group (P = 0.033) but not
the hypoglycemia group (P = 0.974). The rise in WBC
was mainly a consequence of an increase in neutrophil
count (Fig. 6b). The lymphocyte count decreased after
endotoxin (Fig. 6c), and the monocyte count initially
decreased before recovery 6 hours after endotoxin (Fig. 7a).
There was a trend toward a higher total monocyte count
in the hypoglycemia group 4 hours after endotoxin
compared with euglycemia, but this comparison did not
reach statistical significance (P = 0.085). The absolute
number of circulating monocyte subsets did not differ
significantly between study groups (Fig. 7b, 7c, and 7d).
NCM and IM numbers decreased significantly after
endotoxin compared with baseline values in all groups
(P , 0.001) (Fig. 7b and 7c). Compared with baseline,
CM numbers significantly declined at 2 hours (P ,
0.001), before rising and reaching a peak at 6 hours (P,
0.001) (Fig. 7d).
Cell surface markers
We examined monocyte activation after endotoxin
exposure by measuring cell surface marker CX3CR1
expression. Endotoxin administration caused a signifi-
cant decline in expression of this marker across all study
groups compared with baseline (P , 0.001) (Supple-
mental Fig. 2a). This decline was accompanied by an
increase in the concentration of CX3C chemokine ligand
1 in plasma at 4 and 6 hours compared with baseline in
all groups (P, 0.001) (Supplemental Fig. 2e). Activation
of monocytes was also revealed by increased expression
of CD11b expression at 4 and 6 hours after endotoxin
compared with baseline in all groups (P , 0.001)
(Supplemental Fig. 3a). In addition, the percentage of
total monocytes that were positive for CD11b expression
was higher in hypoglycemia group than in the euglycemia
group at 2 hours after endotoxin (P = 0.007) (Supple-
mental Fig. 3b).
Discussion
Hypoglycemia may contribute to exacerbations of ische-
mic CV disease. We aimed to investigate the effect of acute
experimental hypoglycemia and subsequent low-dose
endotoxemia on aspects of the innate immune response
(total leukocytes, leukocyte subsets, and specifically mono-
cyte subsets), thrombosis (platelet aggregation), and crosstalk
Figure 3. Total monocyte count and monocyte subset kinetics in experimental hypoglycemia groups and controls. Absolute circulating numbers
of (a) total monocytes and monocyte subsets (b) NCM, (c) IM, and (d) CM after 60 min of hypoglycemia, euglycemia, or sham-saline injection.
Data are mean (SEM). *P , 0.05; **P , 0.01; ***P , 0.001; P values are provided for comparison between study groups. Black circles,
hypoglycemia group; open circles, euglycemia group; black triangles, sham-saline group.
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9
between inflammation and thrombosis (MPAs). Our main
findings were that hypoglycemia increased the number
of all three circulating monocyte subsets, in association
with a stress response characterized by increased plasma
epinephrine levels; hypoglycemia increased platelet re-
activity, promoted formation of MPAs, and promoted
aggregate formation between proinflammatory mono-
cytes and platelets; leukocyte mobilization to the stress
response of low-dose endotoxin was independent of
epinephrine; and antecedent hypoglycemia resulted in a
significantly higher inflammatory leukocyte response to
low-dose endotoxin administered 48 hours later.
As shown previously (13, 37), we confirm that
hypoglycemia results in leukocytosis. In addition, we
present the effect of hypoglycemia on monocyte subset
kinetics and demonstrate an increase in the absolute
number of all three circulating monocyte subsets. The
largest increase was observed in numbers of circulating
NCMs (twofold) and IMs (1.8-fold), with a modest in-
crease in the number of CMs (1.3-fold). These data are
in keeping with an observed selective mobilization of
CD16+ monocytes in response to exercise (27, 38) and
epinephrine infusion (39). Ratter et al. (37) also recently
determined that hypoglycemia might modify selective
monocyte mobilization. However, they did not pheno-
type monocyte subsets but rather measured total levels of
CD16 on peripheral blood mononuclear cells isolated
from both healthy participants and those with type 1
Figure 4. Platelet reactivity and MPA formation in experimental hypoglycemia and controls. (a) Total platelet count, (b) platelet aggregation to
ADP 6.45 mM, (c) total MPA formation, and MPA formation within monocyte subsets (d) NCM-MPA, (e) IM-MPA, and (f) CM-MPA after 60 min
of hypoglycemia, euglycemia, or sham-saline injection. Data are mean (SEM). *P , 0.05; **P , 0.01; ns, nonsignificant; P values are provided
for comparison between study groups. Black circles, hypoglycemia group; open circles, euglycemia group; black triangles, sham-saline group.
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9
diabetes in experimental hypoglycemia settings. Our data
identify specific changes in monocyte subsets that have
been previously linked to monocyte activation and
atherogenesis. Because observational data support the
notion of CD16+ monocytes being proatherogenic (20,
22–24), and adrenergic modulation of monocytes induces
Figure 5. Changes in epinephrine, cortisol, and GH response after
endotoxin challenge. (a) Epinephrine, (b) cortisol, and (c) GH responses
2, 4, and 6 h after low-dose (0.3 ng/kg) intravenous endotoxin
challenge in participants who underwent hypoglycemia, euglycemia, or
a sham-saline clamp 48 h earlier. Data are mean (SEM). **P , 0.01;
ns, nonsignificant; P value on dashed line in (b) represents change in
cortisol at 4 h compared with baseline in all groups; solid horizontal
lines represent significance for comparison between study groups.
Dashed line in (a) illustrates the mean epinephrine response in the
hypoglycemia clamp group. Black circles, hypoglycemia group; open
circles, euglycemia group; black triangles, sham-saline group.
Figure 6. Peripheral total WBC, neutrophil, and lymphocyte kinetics
after endotoxin challenge. Number of circulating (a) total WBCs,
(b) neutrophils, and (c) lymphocytes 2, 4, and 6 h after low-dose
(0.3 ng/kg) intravenous endotoxin challenge in participants who
underwent hypoglycemia, euglycemia, or a sham-saline clamp 48 h
earlier. Data are mean (SEM). *P , 0.05; ns, nonsignificant; P
values are provided for comparison between study groups; solid
horizontal line in (c) represents significance for comparison between
study groups. Black circles, hypoglycemia group; open circles,
euglycemia group; black triangles, sham-saline group.
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proinflammatory changes (40), an increase in the cir-
culating number of these cells after hypoglycemia may
increase CV risk in diabetes.
Previous studies investigating effects of hypoglycemia
on platelet biology have suggested an increase in platelet
reactivity; however, this increase was in the context of
hypoglycemic stimulus as part of an insulin stress test
(41). An older investigation into the effect of hypogly-
cemia on monocyte-platelet interactions in type 1 di-
abetes and healthy controls also suggested a trend toward
increased MPA formation, but these data were not
conclusive, with little difference between euglycemic and
hypoglycemic conditions (42). Our study also recapitulates
and extends previous findings that hypoglycemia is pro-
thrombotic, as evidenced by an increased platelet count and
increased platelet reactivity to ADP (43). We have con-
clusively demonstrated an overall increase in formation of
MPAs in hypoglycemia in comparison with euglycemia.
Furthermore, we provide data demonstrating MPA
formation within monocyte subsets in experimental
hypoglycemia. MPA formation is a highly sensitive
marker of both monocyte and platelet activation (44,
45). MPA formation promotes monocyte release of the
proinflammatory cytokines TNFa, C-X-C motif che-
mokine ligand 8, and C-Cmotif chemokine ligand 2 (46,
47) and increases adhesive properties of monocytes
(48), thereby representing a bridge between inflammation
and thrombosis that may increase CV risk. In acute
coronary syndromes, MPA formation correlates with
troponin elevation, risk of in-hospital cardiac events in-
cluding death, and risk of future cardiac events (20, 49).
We have also shown that NCMs and IMs aggregate more
readily with platelets in response to hypoglycemia com-
pared with CMs. A similar observation of proportionally
higher IM-MPA and NCM-MPA formation has been
reported in patients after an ST elevation myocardial in-
farction, with higher IM-MPAs in particular being a poor
prognostic indicator at 6 weeks after ST-elevation myo-
cardial infarction (20). Thus, our data suggest that hy-
poglycemia not only increased circulating numbers of
CD16+ monocytes but also promoted increased in-
teraction between these proinflammatory monocyte sub-
sets and platelets.
We wanted to determine whether antecedent hypo-
glycemia modulated responses to low-dose endotoxin.
We chose a low-dose endotoxin model because we
thought it was the safest way to combine the clamp and
endotoxin human models, because future extension to
the study of human diabetes would be more feasible with
this model, and because patients with diabetes are often
exposed to chronic low-grade infections through foot
ulceration and periodontitis, which might further increase
Figure 7. Total monocyte count and monocyte subset kinetics after endotoxin challenge. Absolute circulating numbers of (a) total monocytes
and monocyte subsets (b) NCM, (c) IM, and (d) CM 2, 4, and 6 hours after low-dose (0.3 ng/kg) intravenous endotoxin challenge in participants
who underwent hypoglycemia, euglycemia, or a sham-saline clamp 48 h earlier. Data are mean (SEM). ***P , 0.001; ns, nonsignificant; P value
on dashed line in (b) represents change in number of NCMs at 2, 4, and 6 hours compared with baseline in all study groups. P value on dashed
line in (c) represents change in number of IMs at 2, 4, and 6 h compared with baseline in all study groups. P values on dashed lines in (d)
represent change in number of CMs at 2 and 6 h compared with baseline in all study groups. Solid horizontal lines represent significance for
comparison between study groups. Black circles, hypoglycemia group; open circles, euglycemia group; black triangles, sham-saline group.
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9
the risk of CV mortality (50, 51). In our model, we ob-
served in all groups that monocytes were activated even in
response to low-dose endotoxin, as indicated by upre-
gulation of systemic levels of the CX3CR1 ligand, CX3C
chemokine ligand 1, and upregulation of the adhesion
molecule CD11b on the monocytes themselves. In-
terestingly, compared with euglycemia, hypoglycemia
resulted in greater leukocyte mobilization in response to
low-dose intravenous endotoxemia 48 hours later. Fur-
thermore, we noted a nonsignificant trend toward a higher
total monocyte count in the hypoglycemia group 4 hours
after endotoxin compared with euglycemia. The per-
centage of monocytes that were CD11b positive was also
higher in the hypoglycemia group compared with the
euglycemia group at 2 hours after endotoxin. Levels of
leukocyte mobilization were similar between groups who
received previous sham-saline or hypoglycemia. These
data suggest that euglycemia with insulin suppressed
leukocyte mobilization in response to endotoxin 48 hours
later, consistent with the known anti-inflammatory actions
of insulin (52, 53), and that the physiological stress of
hypoglycemia overcame this insulin-mediated suppression
of inflammatory responses. Our data show that drivers for
differential leukocyte mobilization to endotoxin are un-
likely to be due to differences between groups in epi-
nephrine, cortisol, and GH levels after endotoxin because
these levels were not significantly different. Our obser-
vation that a single episode of hypoglycemia compared
with euglycemia invokes a stronger proinflammatory re-
sponse to endotoxin up to 2 days later is of potential
clinical relevance given that trial data suggest downstream
mortality after hypoglycemia (29–31).
The strengths of our study include use of a human
experimental model and detailed flow cytometric anal-
ysis that allowed us to comprehensively describe immune
cell kinetics and activation status in response to experi-
mental hypoglycemia and endotoxin challenge in vivo.
The separation of clamp and endotoxin studies by 48 hours
allowed us to probe the longitudinal effects of hypoglycemia
on innate immunity. Moreover, by using a sham-saline
group, we specifically controlled for the immunological
effects of insulin, thereby robustly investigating proin-
flammatory changes in response to hypoglycemia.
One limitation was our decision to study a small
number of young, healthy participants, which limits the
applicability of our findings to older patients with di-
abetes, established CV risk factors, and atherosclerosis.
For ethical and safety reasons, we decided to examine our
experimental model initially in healthy participants. We
also specifically adopted a low-dose endotoxin model,
with future translatability in older, higher-risk partici-
pants in mind. Future studies should therefore confirm
our findings in patients with diabetes. In addition, it is
worth noting that we studied cell numbers, phenotypic
changes, and activation status in circulating immune cells,
and these data may not necessarily reflect the functional
capacity of these cells in an atherosclerotic plaque. An
animal model of combined experimental hypoglycemia
and atherosclerosis may help resolve these questions.
In conclusion, hypoglycemia mobilized proathero-
genic monocyte subsets and induced prothrombotic changes
by increasing platelet reactivity. In addition, hypoglycemia
amplified interactions between platelets and monocytes
by promoting MPA formation with increased aggre-
gation of proinflammatory monocytes with platelets.
Hypoglycemia may also prime the innate immune sys-
tem to respond more robustly to stimuli such as en-
dotoxin. This finding implies proinflammatory consequences
of hypoglycemia beyond the acute episode. These data pro-
vide mechanistic insights into how hypoglycemia could
increase CV risk through upregulation of inflammatory
responses.
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